1.2. VDACs as Main Players in Mediating and Regulating Mitochondrial Functions with Cellular Activities
1.2. Le VDAC come attori principali nella mediazione e nella regolazione delle funzioni mitocondriali con attività cellulari
TheLa location in the OMM allows thposizione nell'OMM consente alle proteine VDAC proteins to act as anchor points fo di agire come punti di ancoraggio per diverse sets ofi insiemi di molecules thatole che interact withgiscono con i mitochondria. In this way, VDACs are able toondri. In questo modo, i VDC sono in grado di mediate and regulate the re e regolare l'integration ofzione delle funzioni mitochondrial functions withi con le attività cellular activi.
L'inties.
Theerattoma VDAC interactome includesomprende proteins locatede situate in OMM, innermembrana mitochondrial membranee interna (IMM), ispazio intermembrane spacea (IMS), cyitosol, ereticolo endoplasmic reticulum,atico, membrana plasma membrane andtica e nucleus that are involved ino che sono coinvolti nel metabolismo, apoptosis, signal transduction, trasduzione del segnale, protection againstzione contro ROS, binding tolegame a RNA or DNA, and more DNA e altro ancora.
MLa mobilit
y ofà della regione VDAC N-terminal
α-helix region is ie α-elica è important
for channee per il gating
but also fordei canali, ma anche per le intera
ctions with bothzioni con proteine pro-apoptotic
andhe e anti-apoptotic
proteins such as he come Bax, Bak
, and e Bcl-xL
[15][16][17].
Il VDAC1
is involved in the release ofè coinvolto nel rilascio di fattori apoptotic
factors located in the i localizzati nello spazio intermembran
e space due to its ability ofa grazie alla sua capacità di oligomeriz
ingzarsi in dimer
s, hexamers, and higher-order structures, to form a large pore that allows the passage of cytochrome c and apoptosis inducing factori, esameri e strutture di ordine superiore, per formare un grande poro che consente il passaggio del citocromo c e del fattore di induzione dell'apoptosi (AIF)
to the cyal citosol
ande di conse
quently the activation ofguenza l'attivazione della morte cellulare programm
ed cell death. Insteadata. Invece, VDAC2 fun
ctions asziona come fattore anti-apoptoti
c factor and it is upregulated in severalco ed è sovraregolato in diverse malattie debilita
ting diseases including nti tra cui l'Alzheimer
’s and cancer e il cancro [18].
ThiQues
property ista proprietà è probab
ly due to the unique ability ofilmente dovuta alla capacità unica di VDAC2
todi sequest
er therare la proteina pro-apoptotic
protein Bak in the OMM and maintain it in the inactivea Bak nell'OMM e mantenerla nello stato inattivo state [11].
VDAC1
dimos
plays binding sites, located in its cyttra siti di legame, situati nella sua porzione citosolic
moiety, for manya, per molti enzimi metabolic
enzymes, such as glyi, come la gliceralde
hyde 3-phosphate dehyide-3-fosfato deidrogenas
e, i, la creatin
e kinase, glycerol kinase, glucokinase, c-Raf kinase, and hexokinaschinasi, la glicerolo chinasi, la glucochinasi, la chinasi c-Raf e le isoform
s (I ande e l'esochinasi (I e II),
which need che necessitano di un accesso preferen
tial access to mitochziale all'ATP mitocondrial
e ATP [19].
HL'e
xokinasesochinasi intera
cts through its hydrophobicgisce attraverso la sua sequenza idrofobica N-terminal
sequence with e con Glu
73 ofdi VDAC1,
a binding situn sito di legame localiz
ed on one side of the barrel wall, buried in the hydrophobic environment ofzato su un lato della parete della canna, sepolto nell'ambiente idrofobo di OMM
[20].
IÈ st
has been demonstrated that treatment ofato dimostrato che il trattamento dei mitoc
hondria with dicyclohexyondri con dicicloesilcarbodiimide (DCCD) in
hibits hexokinase–VDAC ibisce l'intera
ction due to selective chemicalzione esochinasi-VDAC a causa della modifica
tion of G chimica selettiva della glu
73 [21].
GIl
u73 residu
eo is alsodi glu73 è tanche
binding site for il sito di legame per le ceramid
es, tumor sui, lipidi oncosoppressor
lipids able to act directly oni in grado di agire direttamente sui mitoc
hondria to trigger apoptotic cell death. It is interesting that both ondri per innescare la morte delle cellule apoptotiche. È interessante notare che sia VDAC1
and 2 own, in a similar position, a cysteineche 2 possiedono, in una posizione simile, un residu
eo di cisteina (Cys
127 in
human el VDAC1
andumano e Cys
138 in
human VDAC2) in the form of suel VDAC2 umano) sotto forma di acido solfonic
acid with a strongo con una forte carica negativ
e charge resembling that of the a simile a quella del residuo acido glutam
atemato acid residue [22]. In
stvece
ad, VDAC3 , l'isoform
does not show anya VDAC3 non mostra alcun residu
e ho omologo
us to a Cys
127/138 o
r Glu
73 incorporato ne
mbedded in the hydrophobic moiety of the lla porzione idrofobica dell'OMM.
VDAC1 present
a una tas
a chca legante il colesterol
binding pocket formed, in human o formata, in isoform
, bya umana, da residui di Ile
123, ,Leu
144, ,Tyr
146, ,Ala
151,e and Val
171 r[ 23].
Mmitoc
hondrial
porins formi formano comple
xes with otherssi con altre protein
s, such as the adeninee, come il nucleotide translocase
dell'adenina (ANT),
the tranla proteina traslocat
or proteinrice (TSPO),
also known as the peripheral-typnota anche come recettore delle benzodiazepine
receptordi tipo periferico (PBR),
mitochHSP70 mitocondrial
HSP70, and several cytoskeletale e diverse protein
s such ase citoscheletriche come tubulin
a, actin
, dynein light chain, anda, catena leggera della dineina e gelsolin
a [11].
ThLa prote
tranina traslocat
or proteinrice intera
cts directly with all VDAC gisce direttamente con tutte le isoform
se VDAC. In partic
ular, olare, l'intera
ction betweenzione tra TSPO
ande VDAC1 contribu
tes to regulate the eisce a regolare l'efficien
cy of mitochondrialza dei meccanismi di controllo della qualit
y control mechanisms and inhibits mitophagyà mitocondriale e inibisce la mitofagia, preven
ting endo l'ubiquitina
tion ofzione delle protein
s throughe attraverso la downregulation
of thedella via PINK1/Parkin
pathway [24].. Il Themotivo GxxxG
motifsi present
s both a sia in VDAC
andche in TSPO,
and ised è necessar
y for thisio per questa intera
ctionzione [25].
MIno
reoverltre, VDAC1
ande TSPO, in associa
tion withzione con StAR (steroidogenic acute regulatory protein), form
the transduceosome, aano il trasdusoma, un complesso multi
-protei
n complex involved in chco coinvolto nel trasporto del colesterol
transport. In a former hypothesiso. In una precedente ipotesi, VDAC1
ande TSPO in OMM, ANT in IMM
, and e Cyclophilin D
in thnella matrice mitoc
hondrial
matrix weree erano candidat
es to constitute the permeabilityi a costituire il poro di transi
tion porezione di permeabilità (PTP),
a high un poro ad alta condu
ctance and non-ttanza e non specific
pore that allowso che consente il gonfiore mitoc
hondrial
swelling and release ofe e il rilascio di proteine apoptogenic
proteins. More recently, it washe. Più recentemente, è stato propos
ed that PTP could bto che il PTP potesse essere form
ed by dimers of theato da dimeri del complesso ATP s
ynthaseintasi complex [26].
Recent
i studi
es have focused attention on the role of VDAC proteins in hanno focalizzato l'attenzione sul ruolo delle proteine VDAC nella disfunzione mitoc
hondrial
dysfunction typical of many pathe tipica di molte condizioni patologic
al conditions including strokehe tra cui ictus, canc
er, mitochro, encefalomiopatie mitocondrial
encephalomyopathies, and aging, as well as i e invecchiamento, nonché disturbi neurodegenerativ
e disordersi [27][28].
ML'ana
ss speclisi della spettrometr
y analysis revealed the ia di massa ha rivelato l'associa
tion between VDACs and the zione tra VDAC e l'ubiquitin
a ligas
ei Parkin. In presen
ce of damagedza di mitoc
hondria, as inondri danneggiati, come nel morbo di Parkinson
’s disease,, La Parkin
is phosphorylated bya viene fosforilata da PINK1
ande di conse
quentlyguenza ubiquitina
tes le protein
s that reside on the OMM, targeting thee che risiedono sull'OMM, prendendo di mira i mitoc
hondria for ondri per la degrada
tionzione. Parkin
is a cy è una proteina citosolic
protein but translocates to thea ma trasloca nei mitocondri per partecipare ai meccanismi di controllo della qualità mitocondriale. Le proteine VDAC rappresentano un sito di attracco di Parkin sui mitoc
hondria toondri difettosi [29].
Moreover, VDAC1 rep
ar
ticipate in esents the main docking site at the mitochondrial
quality control mechanisms. VDAClevel for misfolded and aggregated proteins
represent a docking site of, a common feature of neurodegenerative disorders known as proteinopathies, such as Alzheimer’s disease (AD), Parkin
on defective mitochondriason’s disease (PD), Creutzfeldt–Jacob disease (CJD), dementia with Lewy bodies (DLB), Huntington disease (HD), and amyotrophic lateral sclerosis (ALS) [29].
.
For example, in AD post-mortem brains, in neuroblastoma cells and in an AD mouse model, a direct association was demonstrated between VDAC1, specifically its N-terminal region, and hyper-phosphorylated Tau but also with amyloid beta (Aβ), both in its monomeric and oligomeric forms
[31]. These interactions can have a dramatic effect on mitochondrial functions in AD neuron because they block the PTP formation, disrupt the transport of mitochondrial proteins and metabolites, and impair gating, conductance, and physiological interactome of VDACs
[32].
In Parkinson’s disease, α-synuclein directly interacts with mitochondria, blocks VDAC1, and impairs metabolite fluxes leading, consequently, to an energetic crisis able to compromise cell viability
[33].
In ALS, several SOD1 mutants are able to bind VDAC1
[34]. This interaction impairs ATP/ADP exchange, VDAC1 conductance and mitochondrial membrane potential. Recently, the competition between SOD1G93A and HK1 was demonstrated in binding VDAC1, in NSC34 motor-neuron cell lines
[35].
In literature, the role of VDAC1 in neurodegeneration is rather well known; however, the involvement of the other two isoforms in these pathways remains poorly defined. This is likely associated with the relative abundance of VDAC1 compared to other isoforms which are more difficult to isolate in pure form.
Recent studies demonstrated that Cytoskeleton-associated protein 4 (CKAP4), a palmitoylated type II transmembrane protein localized to the endoplasmic reticulum (ER), regulates mitochondrial functions through an interaction with VDAC2 at ER-mitochondria contact sites
[36].
VDAC2 binds inositol trisphosphate receptors (IP3R) and regulates the release of Ca
2+ from the ER. In addition, several other interaction partners have been reported for VDAC2 isoform, which imply its effect in multiple cellular functions. Specifically, VDAC2 has been linked to many cellular proteins, including apoptotic factors as Bak and Bax, StAR, Metaxin2, eNOS (nitric oxide synthesize), GSK3β, tubulin, and Mcl1
[19]. In addition, VDAC2 and RACK1 (receptor of activated protein kinase C1) function as receptors for lymphocystis disease virus (LCDV) and for bursal disease virus in host cells
[37].
VDAC2 together with VDAC3 binds Erastin, the activator of ferroptosis, a new pathway that regulates cell death characterized by the iron-dependent accumulation of lipid hydroperoxides. Interaction between VDAC2/3 and Erastin results in degradation of the channels following activation of ubiquitin protein ligase Nedd4
[38].
Finally, the VDAC3 isoform is associated with cytosolic proteins as tubulins and cytoskeletal proteins, stress sensors, chaperones, and proteasome components, redox-mediating enzymes such as protein disulfide isomerase
[39].
2. Proteomics of VDAC Isoforms
2.1. Sample Preparation
Sample preparation has a profound effect on the final results of a proteomic workflow. Protein extraction methods and protein separation techniques should provide an unbiased and reliable map representative of all proteins present in a specific sample. The different extraction and fractionation approaches are based on proteins physicochemical and structural characteristics, such as molecular weight, solubility, hydrophobicity, and isoelectric point. A specific protocol has to be optimized for each particular sample, to maximize protein recovery and minimize the possible proteolysis and amino acid modifications. For these reasons, there is no universal extraction protocol and not a unique buffer composition. Regarding the extraction method, the different strategies available need to be compatible with both the amount of the processed material and the subsequent analytical approach (i.e., separation or MS).
The structural characterization of VDACs presents challenging issues due to their very high hydrophobicity, low solubility, and the impossibility to separate them from other mitochondrial proteins of similar hydrophobicity and to easily isolate each single isoform. In fact, isolation of VDACs has been possible exclusively for plant VDAC isoforms by chromatofocusing, thanks to the absence of phosphorylation sites in their structure
[40]. Consequently, it is necessary to analyze them as components of a relatively complex mixture.
A bottom-up proteomic approach was used to investigate the VDAC3 from rat liver mitochondria (rVDAC3)
[41]. According with a standard procedure
[42], mitochondria were extracted and lysed with a buffer containing 3% Triton X-100 at pH 7.0. The VDAC proteins were partially purified by hydroxyapatite (HTP) chromatography, which allows to obtain a VDACs enriched fraction which comprises also other mitochondria hydrophobic proteins. After precipitation with cold acetone, the protein pellet was solubilized in SDS buffer and loaded on a 17% polyacrylamide gel (1D-SDS-PAGE). The bands in the range 30–35 kDa were manually excised from the gel, cut in small pieces, and subjected to reduction with DTT and alkylation by addition of IAA. Finally, the reduced and carboxyamidomethylated proteins were in gel-digested using trypsin and chymotrypsin, and the resulting peptide mixtures were analyzed by nUHPLC/HRMS
[41]. MS data showed that rVDAC3 was found in the whole range 30–35 kDa, together with other proteins, mainly VDAC1, VDAC2, and several other mitochondrial proteins. The reason for VDAC3 electrophoretic heterogeneity probably stems from (i) the different pattern of cysteine oxidations that can modify the protein mobility; (ii) the different amount and quality of cysteine oxidations in various molecules (“redox isomers”).
The gel-digestion procedure shows some disadvantages: (i) larger peptides can get trapped between the gel meshes and lost during the extraction phase of the peptides from the gel; (ii) the electrophoretic procedure itself could damage the samples and alter the redox state of the sulfur amino acids (due to possible over heating generated by the applied voltage and to the presence of residual quantities of the catalysts used for the polyacrylamide polymerization). Furthermore, electrophoresis requires a relatively high amount of sample and the utilization of dyes and detergents. These last molecules could interfere with subsequent MS analyses because these compounds are difficult to eliminate from the sample.
2-DE could potentially represent a useful alternative to 1-DE to improve the separation of VDAC isoforms, but its utilization presents other problems. Actually, this kind of proteins has been under-represented in 2-DE gels due to difficulties in extracting and solubilizing them in the isoelectric focusing sample buffer. In fact, the most effective solubilizing agent for highly hydrophobic membrane proteins is SDS, but this detergent is incompatible with 2-DE. In addition to the difficulties in entering IPG (immobilized pH gradient) gels, membrane proteins tend to precipitate at their isoelectric point during IEF. Furthermore, their tendency to absorb the IPG matrix prevents their migration into the SDS-PAGE gel.
An improvement in the rVDAC3 mass spectrometric analysis was obtained following the introduction of a gel-free shotgun proteomic approach
[41]. According to this procedure, to avoid any possible artefact due to air exposure and manipulations, reduction/alkylation was carried out before VDACs purification from the mitochondria. Afterwards, all the proteins present in the HTP eluate, without previous electrophoretic separation, were purified from non-protein contaminating molecules with the PlusOne 2-D Clean-Up kit, and the desalted protein pellet was then re-dissolved in ammonium bicarbonate containing RapiGest SF to improve the solubility. In fact, this surfactant makes the proteins more susceptible to enzymatic cleavage without modifying the sample or inhibiting endoprotease activity. Furthermore, the RapiGest SF is compatible with enzymes such as trypsin or chymotrypsin and does not influence subsequent MS analysis because it can be easily removed in acidic conditions.
Separate aliquots of reduced and alkylated proteins were then subjected to digestion with modified porcine trypsin and chymotrypsin. In this experiment, every protein in the HTP eluate was digested, producing a very complex peptide mixture, which was finally analyzed by nUHPLC/HR nESI-MS/MS.
The new “in solution-digestion” protocol associated with nUHPLC/HR ESI-MS/MS allowed to extend the coverage of the rat and human VDACs sequences with respect to that obtained with the previous procedure
[43], so that it was possible to completely cover the rat and human VDAC1 sequences and almost completely the rat and human VDAC2 and VDAC3 sequences
[22][41][44]. It should be noted that the short regions not identified in VDAC2 and VDAC3 correspond to small tryptic or chymotryptic peptides or even to single amino acids, which cannot be detected in LC/MS analysis.
Moreover, by means of this new procedure a detailed characterization of PTMs of the three VDACs was obtained (see next paragraphs).
2.2. Mass Spectrometry Analysis of Post-Translational Modifications
The mammalian proteome is vastly more complex than the related genome. The reasons for this difference reside both in the molecular mechanisms that allow a single gene to encode for multiple proteins (genomic recombination, transcription initiation at alternative promoters, differential transcription termination, and alternative splicing of the transcript) and in the post-translational modifications (PTMs) which represent a wide range of chemical changes that proteins can undergo after synthesis. They include the specific cleavage of protein precursors, the covalent addition or removal of low-molecular weight groups (i.e., acetylation, glycosylation, hydroxylation, phosphorylation, ubiquitination) and the formation of disulfide bonds or other redox modifications
[45][46][47].
PTMs play crucial roles in cell biology since they can change protein physical or chemical properties, activity, localization, and/or stability. Traditionally, PTMs have been identified by Edman degradation, amino acid analysis, isotopic labeling, or immunochemistry. Within recent years, MS has proven to be extremely useful in PTM discovery. Post-translationally modified amino acids always have a different molecular mass than the original, unmodified residues and this mass increment or deficit is usually the basis for the detection and characterization of PTM by MS (commonly by LC-ESI-MS/MS).
MS has several advantages for characterization of PTMs, including (i) very high sensitivity; (ii) discovery of novel PTMs; (iii) ability to identify PTMs and the modified sites, even in complex protein mixtures; and (iv) ability to quantify the relative changes in PTM occupancy at distinct sites. None of the other techniques provide all these features, so the greater majority of the known PTMs have been described by MS
[48].
To improve sensibility, several methods have been developed to enrich the samples in proteins or peptides with specific PTMs prior to MS/MS analysis, such as anti-pY antibodies, IMAC (immobilized metal affinity chromatography) and TiO
2 for phosphorylation
[49][50], affinity capture with lectins for glycosylated proteins
[51], and resin coupled with anti-acetyl-lysine for acetylated proteins
[52]. Although, as previously described, isolation of single isoforms of VDACs cannot be obtained, application of combined HPLC and high-resolution ESI-MSMS analysis has resulted in the identification of several PTM in these proteins. In the following, a summary of the MS-based PTMs characterized in VDACs is reported and the respective biological significance discussed. These results are resumed in
Table 1 and
Figure 1.
Figure 1. Post-translational modifications of human (upper panel) and rattus (lower panel) VDAC isoforms. The image shows only the modified amino acids and their positions with respect to the cytosol, the outer mitochondrial membrane (OMM), and the intermembrane space (IMS). In the rVDAC1 Cys232 faces the aqueous inside of the pore; in the rVDAC3 Cys8 is located inside of the pore.
Table 1. Post-translational modifications in VDAC isoforms obtained using mass spectrometry. PTM type, mass shift (Da), source of the sample, modified residue, MS method and relative reference are reported. Studies are described by listing first author + year.
ISOFORM |
PTM Type |
ΔMass (Da) |
Source |
Residue |
Method |
Study |
VDAC1 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Ala 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Ala 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 33, 41, 74, 234 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 41, 122, 132 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Mouse liver and heart |
Lys 237 |
UPLC Velos-FT MS |
Yang et al., 2011 |
Human liver |
Lys 28 |
LC/LC-MS/MS in an FTICR/MS |
Zhao et al., 2010 |
Oxidation |
15.9949 |
Rat liver |
Met 155 |
LC/LC-MS/MS in an FTICR/MS |
Guan et al., 2003 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Met 129, 155 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 127, 232 |
Saletti et al., 2018 |
HAP1 cells |
Cys 127 |
Pittalà et al., 2020 |
Phosphorylation |
79.9663 |
Rat liver |
Ser 12, 136 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse liver |
Ser 117 |
nHPLC MS/MS in an LTQ MS |
Lee et al., 2007 |
HeLa cells |
Ser 101, 102, 104, Thr 107 |
nHPLC MS/MS in an LTQ-Orbitrap MS |
Olsen et al., 2006 |
Mouse brain |
Tyr 80, 208 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |
VDAC2 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Ala 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Ala 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 32, 75 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 121 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Oxidation |
15.9949 |
Rat liver |
Met 167 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
HAP1 cells |
Met 12, 166 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 48, 77, 104, 211 |
Saletti et al., 2018 |
HAP1 cells |
Cys 47, 76, 103, 138, 210 |
Pittalà et al., 2020 |
Succination |
116.0110 |
Mouse brain |
Cys 48, 77 |
LC-nESI-MS/MS in an LTQ-Orbitrap MS |
Piroli et al., 2016 |
Rat liver |
Cys 48 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2018 |
Phosphorylation |
79.9663 |
HeLa cells |
Ser 115, Thr 118 |
nHPLC MS/MS in an LTQ-Orbitrap MS |
Olsen et al., 2006 |
Rat liver |
Thr 109 |
SCX-RP-MS/MS in an LTQ-Orbitrap MS |
Deng et al., 2010 |
Rat liver |
Tyr 237 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse brain |
Tyr 207 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |
VDAC3 |
Protein N-terminal acetylation |
42.0106 |
Rat liver |
Cys 2 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2016 |
HAP1 cells |
Cys 2 |
Pittalà et al., 2020 |
Acetylation |
42.0106 |
Mouse liver |
Lys 20, 61, 226 |
nHPLC MS/MS in an LTQ MS |
Kim et al., 2006 |
Lys 63, 109 |
nHPLC MS/MS in an LTQ 2D ion-trap MS |
Schwer et al., 2009 |
Human liver |
Lys 28 |
LC/LC-MS/MS in an FTICR-MS |
Zhao et al., 2010 |
Oxidation |
15.9949 |
Rat liver |
Met 26, 155 |
nUHPLC/high resolution nESI-MS/MS in a Q-QT-qIT MS |
Saletti et al., 2016 |
HAP1 cells |
Met 26, 155, 226 |
Pittalà et al., 2020 |
Trioxidation |
47.9847 |
Rat liver |
Cys 36, 65, 165, 229 |
Saletti et al., 2016 |
HAP1 cells |
Cys 36, 65 |
Pittalà et al., 2020 |
Succination |
116.0110 |
Rat liver |
Cys 8, 36, 229 |
Saletti et al., 2018 |
Phosphorylation |
79.9663 |
Rat liver |
Ser 241, Thr 33 |
HPLC MS/MS in an LTQ MS |
Distler et al., 2007 |
Mouse brain |
Tyr 49 |
LC-MS/MS in an LTQ FT MS |
Ballif et al., 2008 |